Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5936
    -0.0001 (-0.02%)
     
  • NZD/EUR

    0.5546
    +0.0001 (+0.01%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.79
    -0.02 (-0.02%)
     
  • GOLD

    2,329.90
    -8.50 (-0.36%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • NZD/JPY

    92.1310
    +0.0160 (+0.02%)
     

Is AbbVie or Amgen the Better Bargain Buy Right Now?

Is AbbVie or Amgen the Better Bargain Buy Right Now?

Due to the highly competitive nature of the pharmaceutical industry, it is no easy task to replace the aging stars in a drug portfolio. Teva Pharmaceutical (NYSE: TEVA) illustrates this point nicely. In the middle of the last decade, Teva lost exclusivity for its multiple sclerosis medication Copaxone.